Dolutegravir/lamivudine (Dovato®), which is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||16/07/2019|
|Rapid review completed||26/08/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommend that dolutegravir /lamivudine (Dovato®) not be considered for reimbursement at the submitted price.*|
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.